Bruker Cellular Analysis (CELL) 10-Q 9 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39388
Entity Registrant Name	Berkeley Lights, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2415390
Entity Address, Address Line One	5858 Horton Street, Suite 320
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	858-2855
Title of 12(b) Security	Common stock, $0.00005 par value
Trading Symbol	BLI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		68,283,926
Entity Central Index Key	0001689657
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 143,024	$ 178,096
Short-term marketable securities	9,361	0
Trade accounts receivable	13,815	25,942
Inventory	15,664	14,547
Prepaid expenses and other current assets	10,606	11,985
Total current assets	192,470	230,570
Restricted cash	0	270
Property and equipment, net	29,317	27,992
Operating lease right-of-use assets	24,522	26,060
Other assets	2,397	2,361
Total assets	248,706	287,253
Current liabilities:
Trade accounts payable	8,499	8,198
Accrued expenses and other current liabilities	11,945	12,425
Deferred revenue	8,694	12,128
Total current liabilities	29,138	32,751
Notes payable	19,794	19,762
Deferred revenue, net of current portion	1,221	2,187
Lease liability, long-term	24,137	24,337
Total liabilities	74,290	79,037
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.00005 par value. Authorized 300,000,000 shares at June 30, 2022 and December 31, 2021; issued and outstanding 68,273,932 and 67,595,535 shares at June 30, 2022 and December 31, 2021, respectively	4	4
Additional paid-in capital	485,212	471,820
Accumulated deficit	(310,781)	(263,608)
Accumulated other comprehensive loss	(19)	0
Total stockholders’ equity	174,416	208,216
Total liabilities and stockholders’ equity	$ 248,706	$ 287,253

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Common stock authorized (in shares)	300,000,000	300,000,000
Common stock issued (in shares)	68,273,932	67,595,535
Common stock outstanding (in shares)	68,273,932	67,595,535

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 19,150	$ 19,250	$ 39,356	$ 37,878
Cost of sales:
Total cost of sales	6,224	6,522	12,603	12,699
Gross profit	12,926	12,728	26,753	25,179
Operating expenses:
Research and development	18,178	13,535	35,751	26,562
General and administrative	13,024	11,725	24,740	20,692
Sales and marketing	7,271	5,317	13,082	10,923
Total operating expenses	38,473	30,577	73,573	58,177
Loss from operations	(25,547)	(17,849)	(46,820)	(32,998)
Other income (expense):
Interest expense	(227)	(356)	(451)	(710)
Interest income	53	43	87	109
Other income (expense), net	(22)	34	35	53
Loss before income taxes	(25,743)	(18,128)	(47,149)	(33,546)
Provision for income taxes	4	26	24	43
Net loss	$ (25,747)	$ (18,154)	$ (47,173)	$ (33,589)
Net loss attributable to common stockholders per share, basic (in dollars per share)	$ (0.38)	$ (0.27)	$ (0.70)	$ (0.51)
Net loss attributable to common stockholders per share, diluted (in dollars per share)	$ (0.38)	$ (0.27)	$ (0.70)	$ (0.51)
Weighted-average shares used in calculating net loss per share, basic (in shares)	67,985,664	66,790,755	67,842,372	66,029,307
Weighted-average shares used in calculating net loss per share, diluted (in shares)	67,985,664	66,790,755	67,842,372	66,029,307
Product revenue
Revenue:
Total revenue	$ 9,468	$ 13,021	$ 19,242	$ 26,554
Cost of sales:
Total cost of sales	2,614	3,332	5,309	7,035
Service revenue
Revenue:
Total revenue	9,682	6,229	20,114	11,324
Cost of sales:
Total cost of sales	$ 3,610	$ 3,190	$ 7,294	$ 5,664

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (25,747)	$ (18,154)	$ (47,173)	$ (33,589)
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax	(19)	0	(19)	0
Other comprehensive loss:	(19)	0	(19)	0
Comprehensive loss	$ (25,766)	$ (18,154)	$ (47,192)	$ (33,589)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020		64,486,246
Beginning balance at Dec. 31, 2020	$ 244,781	$ 3	$ 436,662	$ (191,884)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		2,422,740
Exercise of stock options	8,347	$ 1	8,346
Vesting of restricted stock units (in shares)		19,191
Employee stock purchase plan (in shares)		115,360
Employee stock purchase plan	2,157		2,157
Stock-based compensation	10,143		10,143
Other comprehensive loss	0
Net loss	(33,589)			(33,589)
Ending balance (in shares) at Jun. 30, 2021		67,043,537
Ending balance at Jun. 30, 2021	231,839	$ 4	457,308	(225,473)	0
Beginning balance (in shares) at Mar. 31, 2021		66,384,736
Beginning balance at Mar. 31, 2021	242,366	$ 4	449,681	(207,319)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		644,610
Exercise of stock options	1,985		1,985
Vesting of restricted stock units (in shares)		14,191
Stock-based compensation	5,642		5,642
Other comprehensive loss	0
Net loss	(18,154)			(18,154)
Ending balance (in shares) at Jun. 30, 2021		67,043,537
Ending balance at Jun. 30, 2021	231,839	$ 4	457,308	(225,473)	0
Beginning balance (in shares) at Dec. 31, 2021		67,595,535
Beginning balance at Dec. 31, 2021	208,216	$ 4	471,820	(263,608)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		262,667
Exercise of stock options	766		766
Vesting of restricted stock units (in shares)		300,384
Employee stock purchase plan (in shares)		115,346
Employee stock purchase plan	610		610
Stock-based compensation	12,016		12,016
Other comprehensive loss	(19)				(19)
Net loss	(47,173)			(47,173)
Ending balance (in shares) at Jun. 30, 2022		68,273,932
Ending balance at Jun. 30, 2022	174,416	$ 4	485,212	(310,781)	(19)
Beginning balance (in shares) at Mar. 31, 2022		67,820,115
Beginning balance at Mar. 31, 2022	193,201	$ 4	478,231	(285,034)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		181,013
Exercise of stock options	354		354
Vesting of restricted stock units (in shares)		272,804
Stock-based compensation	6,627		6,627
Other comprehensive loss	(19)				(19)
Net loss	(25,747)			(25,747)
Ending balance (in shares) at Jun. 30, 2022		68,273,932
Ending balance at Jun. 30, 2022	$ 174,416	$ 4	$ 485,212	$ (310,781)	$ (19)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (47,173)	$ (33,589)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	4,431	2,654
Stock-based compensation	11,958	10,123
Amortization of operating lease right-of-use assets	1,538	994
Non-cash interest and other expense related to debt and note receivable agreements	32	36
Provision for excess and obsolete inventory	479	330
Loss on disposal and impairment of property and equipment	27	31
Other non-cash	271	0
Changes in operating assets and liabilities:
Trade accounts receivable	12,128	(6,820)
Inventory	(1,539)	(5,710)
Prepaid expenses, other current assets and other assets	1,340	(639)
Trade accounts payable	1,000	4,512
Deferred revenue	(4,400)	2,942
Accrued expenses and other current liabilities	(585)	1,872
Operating lease liabilities	(95)	(831)
Net cash used in operating activities	(20,588)	(24,095)
Cash flows from investing activities:
Purchase of property and equipment	(6,758)	(4,382)
Purchase of marketable securities	(9,372)	0
Net cash used in investing activities	(16,130)	(4,382)
Cash flows from financing activities:
Payment of debt issuance costs	0	(358)
Proceeds from issuance of common stock upon exercise of stock options	766	8,347
Proceeds from issuance of common stock under employee stock purchase plan	610	2,157
Net cash provided by financing activities	1,376	10,146
Net decrease in cash and cash equivalents and restricted cash	(35,342)	(18,331)
Cash and cash equivalents and restricted cash at beginning of period	178,366	233,678
Cash and cash equivalents and restricted cash at end of period	$ 143,024	$ 215,347

The Company and Basis of Presen

The Company and Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation Description of Business Berkeley Lights, Inc. (the “Company” or “Berkeley Lights”) is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights’ platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including the Company’s OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software. Berkeley Lights and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California. Basis of Presentation The accompanying unaudited condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. Liquidity The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three and six months ended June 30, 2022, the Company had a consolidated net loss of $25.7 million and $47.2 million, respectively, and as of June 30, 2022 had an accumulated deficit of $310.8 million. Unrestricted cash, cash equivalents and marketable securities was $152.4 million at June 30, 2022. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash, cash equivalents and marketable securities balance as of June 30, 2022 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission and have not materially changed during the six months ended June 30, 2022, with the exception of the accounting policies as described further below. Short-Term Marketable Securities The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities within “current assets” on the Company’s condensed consolidated balance sheets. The Company records these securities at fair value and accounts for the net unrealized gains and losses related to them as part of “other comprehensive loss” on its condensed consolidated statement of comprehensive loss. The Company records realized gains and losses on the sale of its marketable securities in “Other income, net” in its condensed consolidated statement of operations. At each reporting date, the Company performs an evaluation of impairment of its short-term available-for-sale marketable debt securities to determine if the fair value of its investment is less than its amortized cost basis. Impairment is assessed at the individual security level. Factors considered in determining whether an investment is impaired include the Company’s intent and ability to hold the investment until the recovery of its amortized cost basis, any historical failure of the issuer to make scheduled interest or principal payments, any change to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer’s industry, and any significant deterioration in economic conditions. Stock-Based Compensation The Company maintains an incentive compensation plan under which stock options and restricted stock units (“RSU”) are granted to employees and non-employee consultants. Stock-based compensation expense is based on the grant date fair value of the award. The Company determines the fair value of RSUs based on the closing value of its stock price listed on the Nasdaq at the date of the grant. The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value. The fair value of stock options and RSUs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis. For performance stock options and awards not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed. The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities Short-Term Marketable Securities The Company invests in available-for-sale marketable debt securities consisting of commercial paper and U.S. government securities with contractual maturities due within one year. The Company did not hold any investments in marketable debt securities as of December 31, 2021. The following table summarizes the amortized costs and carrying value of the Company’s available-for-sale marketable debt securities, by major security type, as of June 30, 2022 (in thousands): As of June 30, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 5,395 $ — $ (8) $ 5,387 U.S. government securities 3,982 — (8) 3,974 Total $ 9,377 $ — $ (16) $ 9,361 At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Unrealized losses on available-for-sale debt securities as of June 30, 2022 were not significant and were primarily market driven due to changes in interest rates, and not due to increased credit risk associated with specific securities. Accordingly, the Company did not record an allowance for credit losses on these short term investments as of June 30, 2022.

Significant Risks and Uncertain

Significant Risks and Uncertainties Including Business and Credit Concentrations	6 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Significant Risks and Uncertainties Including Business and Credit Concentrations	Significant Risks and Uncertainties Including Business and Credit Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term available-for-sale debt securities and trade receivables. The Company’s cash, cash equivalents and short-term available-for-sale marketable securities are held by large, credit worthy financial institutions. The Company invests its excess cash in money market funds and short-term available-for-sale debt securities with the primary objective of facilitating liquidity and capital preservation. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash, cash equivalents and marketable securities. The Company controls credit risk through credit approvals and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected credit losses in its existing trade accounts receivable. At each of June 30, 2022 and December 31, 2021, the Company had not recorded any material allowance for doubtful accounts. Most of the Company’s customers are located in the United States and Asia Pacific. For the three months ended June 30, 2022, three customers accounted for 20%, 11%, and 10% of revenue. For the six months ended June 30. 2022, three customers accounted for 16%, 11% and 10% of revenue. For the three months ended June 30, 2021, three customers accounted for 27%, 18% and 11%, of revenue. For the six months ended June 30, 2021, three customers accounted for 14%, 11% and 10% of revenue.

Revenue From Contracts With Cus

Revenue From Contracts With Customers	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue From Contracts With Customers	Revenue From Contracts With Customers Disaggregation of Revenue The following table depicts the disaggregation of revenue by type of customer or sales channel and market segment as defined by nature of workflows and activities of the end customer (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Type of Sales Channel Direct sales channel $ 14,067 $ 10,103 $ 29,553 $ 20,542 Distributor channel 5,083 9,147 9,803 17,336 Net revenues $ 19,150 $ 19,250 $ 39,356 $ 37,878 Market Antibody therapeutics $ 12,984 $ 13,672 $ 27,209 $ 28,786 Synthetic biology 2,067 1,856 4,539 3,840 Agricultural biology 1,854 — 3,345 — Gene therapy 2,028 2,058 3,802 3,283 Cell therapy 217 1,664 461 1,969 Net revenues $ 19,150 $ 19,250 $ 39,356 $ 37,878 Revenues by market are determined by the revenue associated with workflows that the Company’s customers are utilizing, primarily on the Company’s Beacon platform, or by the nature of the workflows that the Company is developing under strategic partnerships and services agreements. Revenues by geographical markets are presented in Note 16 to these condensed consolidated financial statements. Performance Obligations A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less. As of June 30, 2022, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts in excess of one year w as $6.4 million, which is included in deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 20% is e xpected to be recognized as revenue in the next 12 months, with the remainder recognized afterwards. Contract Balances The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): June 30, December 31, Trade accounts receivable $ 13,815 $ 25,942 Contract assets, which are included in “Prepaid expenses and other current assets” $ 3,765 $ 1,736 Contract assets, long-term, which are included in “Other assets” $ 996 $ 1,070 Deferred revenue (current) $ 8,694 $ 12,128 Deferred revenue (non-current) $ 1,221 $ 2,187 The contract liabilities of $9.9 million and $14.3 million as of June 30, 2022 and December 31, 2021, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements and advanced automation systems arrangements. Revenue recorded during the three and six months ended June 30, 2022 i ncluded $2.7 million and $9.9 million, respectively, of previously deferred revenue that was included in contract liabilities as of December 31, 2021. Sales-type Lease Arrangements The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was none for the three and six months ended June 30, 2022, respectively, and $1.0 million and $2.7 million for the three and six months ended June 30, 2021, respectively. The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of June 30, 2022 (in thousands): Year ending December 31, Sales-Type Remainder of 2022 $ 1,212 2023 445 2024 853 Total undiscounted cash flows 2,510 Less: unearned income 305 Total amounts due from customers $ 2,205

Balance Sheet Accounts

Balance Sheet Accounts	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts Inventory The following table shows the components of inventory (in thousands): June 30, December 31, Raw materials $ 10,861 $ 8,296 Finished goods 4,803 6,251 Total $ 15,664 $ 14,547 Prepaid expenses and other current assets The following table shows the components of prepaid expenses and other current assets (in thousands): June 30, December 31, Contract asset $ 3,765 $ 1,736 Vendor deposits 2,679 2,802 Deferred costs 537 561 Prepaid insurance 399 2,944 Other (1) 3,226 3,942 Total $ 10,606 $ 11,985 (1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT. Accrued expenses and other current liabilities The following table shows the components of accrued expenses and other current liabilities (in thousands): June 30, December 31, Accrued payroll and employee related expenses $ 6,400 $ 6,757 Lease liability – short-term 3,046 2,941 Accrued product warranty 752 1,085 Accrued legal expenses 1,087 504 Other (1) 660 1,138 Total $ 11,945 $ 12,425 (1) Other includes primarily accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value of the Company’s assets and liabilities, including cash equivalents and marketable debt securities, are measured at fair value on a recurring basis. As of June 30, 2022 the Company held investments in securities classified as cash equivalents. The carrying amounts of the Company’s cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities as of June 30, 2022 and December 31, 2021 approximate fair value due to their relatively short maturities. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): June 30, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 32,233 $ 32,233 $ — $ — Commercial paper 22,595 — 22,595 — U.S. government securities 5,986 — 5,986 — Total cash equivalents 60,814 32,233 28,581 — Debt securities, available for sale: Commercial paper 5,387 — 5,387 — U.S. government securities 3,974 — 3,974 — Total debt securities, available for sale 9,361 — 9,361 — Total assets measured at fair value $ 70,175 $ 32,233 $ 37,942 $ — December 31, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 25,138 $ 25,138 $ — $ — Total cash equivalents $ 25,138 $ 25,138 $ — $ — The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): June 30, 2022 December 31, 2021 Carrying Fair Value Carrying Fair Value Long-term debt, including current maturities $ 19,794 $ 19,287 $ 19,762 $ 19,298 The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy. The Company did not have any transfers of financial assets measured at fair value on a recurring basis between the levels of the fair value measurement hierarchy during the periods presented.

Property and Equipment, net

Property and Equipment, net	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net comprised the following (in thousands): June 30, December 31, Equipment, tooling and molds $ 38,599 $ 33,972 Computer software and equipment 2,929 3,019 Furniture, fixtures and other 1,957 1,891 Leasehold improvements 10,820 6,105 Construction in process 778 4,803 Total property and equipment 55,083 49,790 Less: Accumulated depreciation (25,766) (21,798) Property and equipment, net $ 29,317 $ 27,992 Total depreciation expense for the three and six months ended June 30, 2022 was $2.5 million and $4.4, respectively. Total depreciation expense for three and six months ended June 30, 2021 was $1.4 million and $2.7 million, respectively. During the three and six months ended June 30, 2022 and 2021 losses on the impairment and disposal of property and equipment was not material.

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, distribution and laboratory facilities in Emeryville, California under multiple operating leases. During the third quarter of 2021, the Company extended the term for its leases related to the facilities in Emeryville and these leases will now expire in 2029. Also, during the third quarter of 2021, the Company entered into a seven year lease of space for office and laboratory operations in Lexington, Massachusetts. The Company also leases two facilities in Shanghai, China for office and laboratory facilities under operating lease agreements that were entered into in July 2020. These leases expire at various dates, the latest of which is August 2023. Future payments associated with the Company’s operating lease liabilities as of June 30, 2022 is as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, Remainder of 2022 $ 2,101 2023 4,273 2024 4,355 2025 4,486 2026 4,621 Thereafter 12,223 Total undiscounted lease payments 32,059 Less: implied interest (4,811) Less: tenant improvement allowances receivable (65) Present value of operating lease payments 27,183 Less: current portion (1) (3,046) Total long-term operating lease liabilities $ 24,137 (1) Included in the balance sheet caption “Accrued expenses and other current liabilities.” Rent expense for the three and six months ended June 30, 2022 was $1.4 million and $2.5 million, respectively. Rent expense for the three and six months ended June 30, 2021 was $0.9 million and $1.7 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $1.0 million and $1.8 million for the three and six months ended June 30, 2022, respectively, including non-lease components such as common area maintenance fees. Variable lease payments for operating leases were $0.6 million and $1.1 million for the three and six months ended June 30, 2021, respectively, including non-lease components such as common area maintenance fees. The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Six months ended June 30, 2022 Six months ended June 30, 2021 Right-of-use assets obtained for new operating lease liabilities $ — $ — Cash paid for amounts included in the measurement of lease liabilities $ 1,070 $ 796 The following summarizes additional information related to operating leases: June 30, 2022 December 31, 2021 Weighted-average remaining lease term (years) 7.02 7.51 Weighted-average discount rate 4.67 % 4.67 %

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Notes Payable On May 23, 2018, the Company entered into a Loan and Security Agreement with East West Bank (“EWB”) providing it the ability to borrow up to $20.0 million. The loan facility was fully drawn as of May 23, 2018. On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (the “Agreement”) with EWB. Pursuant to the Agreement, EWB provided a $20.0 million term loan (the “Term Loan”) which was used to refinance the term loan outstanding under the Loan and Security Agreement dated May 23, 2018. The Term Loan matures in 48 months and bears a fixed interest rate of 4.17% . The Term Loan has an initial interest-only period of 24 months, which can be extended to up to 36 months based on the achievement of certain liquidity measures, and can be pre-paid without penalty at any time. The Agreement grants EWB a security interest in and liens on all assets of the Company, excluding intellectual property, which is subject to a double negative pledge. In addition, certain other terms of the original agreements as previously in effect were amended by the Agreement, including certain financial covenants. The Amended and Restated Loan and Security Agreement was accounted for as a debt modification and the Company capitalized incremental debt issuance costs. Furthermore, the Agreement also provided the Company with a new $10.0 million revolving credit (the “Revolving Line”), which bears interest on the outstanding daily balance thereof of 0.70% above the Prime Rate (as defined in the Agreement). No amounts were outstanding under the Revolving Line as of June 30, 2022. The Agreement contains certain financial and non-financial covenants. As of June 30, 2022, the Company was in compliance with the terms and covenants of the Agreement. The following is a schedule of payments due on notes payable as of June 30, 2022 (in thousands): June 30, Year Ending December 31: Remainder of 2022 $ 426 2023 6,617 2024 10,406 2025 4,210 Total payments due 21,659 Less: Interest payments, loan discounts and financing costs (1,865) Current portion, less loan discounts and financing costs — Notes payable, net of current portion $ 19,794 Total interest cost incurred for the three and six months ended June 30, 2022 was $0.2 million and $0.5 million, respectively. Total interest cost incurred for the three and six months ended June 30, 2021 was $0.4 million and $0.7 million, respectively.

Stock Compensation Plans

Stock Compensation Plans	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Compensation Plans	Stock Compensation Plans Stock-based compensation Stock-based compensation related to the Company's stock-based awards was recorded as an expense and allocated as follows (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Cost of sales $ 68 $ 63 $ 119 $ 105 Research and development 2,292 1,599 3,873 2,660 General and administrative 2,318 2,497 4,529 3,869 Sales and marketing 1,887 1,470 3,437 3,489 Total stock-based compensation $ 6,565 $ 5,629 $ 11,958 $ 10,123 Stock-based compensation capitalized in inventory was not material as of June 30, 2022 and December 31, 2021. Option Repricing On May 19, 2022, the Company’s Board of Directors elected to reprice all outstanding stock options granted to non-executive employees of the Company under the Berkeley Lights, Inc. 2020 Incentive Plan with a strike price above the closing price of the Company’s common stock as reported on Nasdaq as of May 19, 2022 (which was $4.91). There were no other modifications to these options, including vesting schedules. Options representing 763,307 underlying shares were included in this repricing and the total incremental expense associated with the modification of these options was $1.5 million, of which $0.5 million was recorded in the second quarter of 2022. In addition, non-executive employees with outstanding options granted under the Berkeley Lights 2011 Equity Incentive Plan with a strike price above the closing price of the Company’s common stock as reported on Nasdaq as of May 19, 2022 were granted an RSU for every two stock options held with a strike price above the closing price as of May 19, 2022. These RSUs were granted on June 1, 2022 and vest in full on June 1, 2024. An aggregate total of 353,625 RSUs were granted to such employees resulting in $1.5 million of compensation expense, of which approximately $55 thousand was recorded in the second quarter of 2022. CEO Equity Grant On March 10, 2022, the Company granted the newly appointed Chief Executive Officer of the Company 1,017,177 RSUs, 339,059 stock options and 678,118 performance-based stock options (“PSOs”). The RSUs and stock options vest quarterly over 3 years and the stock options have a 10 year term. The PSOs have a 7-year performance period, a 10-year term and vest based upon certain market conditions and a continued service-based requirement. Market condition-related vesting is triggered based on the Company’s stock price reaching certain goals that range from two to 20 times the Company share price on the date of grant. Although no awards will vest until a market condition is satisfied, as of March 31, 2022 the Company began recording stock-based compensation expense for each vesting tranche based on the estimated achievement date of the specified stock price target. The valuation and probability of achievement for each tranche is determined using a Monte Carlo simulation. The same Monte Carlo simulation is used as the basis for determining the expected achievement date. As the probability of achievement is factored in as part of the Monte Carlo simulation, the expense for these tranches will be recognized concurrently over each tranche’s estimated achievement date even if

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company’s provision for income taxes was $4,000 and $24,000, respectively, for the three and six months ended June 30, 2022 and $26,000 and $43,000, respectively, for the three and six months ended June 30, 2021. For the three and six months ended June 30, 2022 and 2021, income from operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of this allowance.

Statements of Cash Flows

Statements of Cash Flows	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Statements of Cash Flows	Statements of Cash Flows The supplemental cash flow information consists of the following (in thousands): Six months ended June 30, 2022 2021 Cash paid for interest $ 278 $ 681 Cash paid for income taxes $ — $ 3 Non-cash investing and financing activities Inventory transferred to property and equipment (1) $ — $ 3,827 Change in accounts payable and accrued liabilities related to purchases of property and equipment $ (699) $ 723 (1) The non-cash transfer of inventory to property and equipment principally relates to Beacons that were transferred to the Company’s BioFoundry operations in the first and second quarter of 2021. As a result of the growth of the Company’s BioFoundry operations, including growth in the number of Beacons used to fulfill strategic partnerships and services agreements, beginning in the third quarter of 2021, Beacons that at inception are planned to be used in the Company’s BioFoundry operations will be categorized as “Purchase of property and equipment.”

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred. AbCellera Biologics Litigation In July 2020, AbCellera Biologics Inc. (“AbCellera”) filed a complaint in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936 and 10,704,018 (“AbCellera I”). In August 2020, AbCellera filed a second complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,718,768, 10,738,270, 10,746,737, and 10,753,933 (“AbCellera II”). In September 2020, AbCellera filed amended complaints in each of AbCellera I and AbCellera II adding The University of British Columbia (“UBC”) as a named plaintiff. Also in September 2020, AbCellera and UBC filed a third complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,775,376, 10,775,377, and 10,775,378 (“AbCellera III”). AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the AbCellera I, AbCellera II and AbCellera III lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents and for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct. The Company filed a motion to transfer the AbCellera I, AbCellera II and AbCellera III lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (the “consolidated lawsuit”). On May 6, 2021 and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. On July 1, 2021, the court granted the Company’s motion to amend its answer and counterclaims to add federal and state unfair competition counterclaims against AbCellera Biologics; on July 22, 2021, the Company filed its amended answer and counterclaims. Also on July 1, 2021 the court issued a Case Management Order that, among other things, requires AbCellera and UBC to reduce the number of asserted patents to no more than two, and the total asserted patent claims to no more than four per patent prior to the trial. Also in July 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the United States Patent & Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent No. 10,421,936, then filed a motion in the district court to stay the consolidated lawsuit pending the outcome of the IPR proceedings. In August 2021, the Company filed a third petition for IPR with the USPTO, challenging the validity of all asserted claims of U.S. Patent No. 10,739,270. Also in August 2021, the court granted the Company’s motion to stay the consolidated AbCellera I, AbCellera II, and AbCellera III lawsuits pending the outcome of the IPR proceedings. In January 2022, the Patent Trial and Appeal Board (“PTAB”) of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10,421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. In May 2022, UBC filed a Patent Owner’s Response (“POR”) in the IPR of U.S. Patent No. 10,087,408. Also in May 2022, AbCellera and UBC filed a motion in the United States District Court for the Northern District of California to lift the stay of the consolidated AbCellera I, AbCellera II, and AbCellera III lawsuits, citing lack of institution of the IPRs of U.S. Patent Nos. 10,421,936 and 10,739,270. The Company has opposed the motion, and a hearing on the motion to lift the stay is scheduled for August 2022. In August 2020, the Company filed a complaint in the United States District Court for the Northern District of California against AbCellera and Lineage BioSciences, Inc., an entity previously acquired by AbCellera (“AbCellera IV”). The complaint included two counts of unfair competition and one count of a declaratory judgment of non-infringement of U.S. Patent No. 10,058,839. The Company was seeking, among other things, damages and a judgment of non-infringement. In October 2020, the Company filed an amended complaint asserting the same three counts and AbCellera and Lineage filed a motion to dismiss the amended complaint, which was granted, without prejudice, in part. In light of the Company’s amended answer and counterclaims in the consolidated lawsuits, which were amended to include its federal and state unfair competition claims as discussed above, in July 2021 the Company filed a notice of dismissal without prejudice in the AbCellera IV lawsuit, resulting in its termination. The Company believes that the patent assertions by AbCellera and UBC are without merit and intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of its products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. Securities Class Action In December 2021, Victor J. Ng filed a securities class action complaint (the “Securities Class Action”), which was amended on July 25, 2022. The Securities Class Action is on behalf of all persons who purchased or otherwise acquired: (a) Berkeley Lights common stock pursuant and/or traceable to certain July 2020 IPO offering documents and/or (b) securities of Berkeley Lights between July 17, 2020 and January 5, 2022, inclusive. The complaint alleges claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder as well as §§11, 12(a)(2) and 15 of the Securities Act of 1933. It names as defendants the Company, certain of the Company’s current and former senior executives and directors, the underwriter firms that sponsored the Company’s July 2020 IPO, and three firms that invested in the Company. The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. Derivative Action In March 2022, Trung Nguyen filed a shareholder derivative complaint on behalf of nominal defendant Berkeley Lights, Inc., alleging that certain of the Company’s current and former directors and certain of the Company’s current and former senior executives breached their fiduciary duties to the Company. The complaint also alleged that certain of the Company’s current and former directors and former senior executives used material, non-public information to improperly profit from the sale of Company stock, and that certain of the Company’s current and former senior executives owe the Company contribution for violations of sections 10(b) and 21D of the Securities Exchange Act of 1934. The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity. No provision has been made for litigation because the Company believes that it is not probable that a liability had been incurred as of June 30, 2022. Product Warranty The Company provides a 13-month assurance-type warranty, generally beginning on the shipment date, on its platforms and chip consumables. The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Balance, beginning of period $ 914 $ 1,268 $ 1,085 $ 1,271 Adjustments to existing warranties (185) (148) (430) (366) Provision for new warranties 179 242 342 617 Settlement of pre-existing warranties (156) (172) (245) (332) Balance, end of period $ 752 $ 1,190 $ 752 $ 1,190

Net Loss Attributable to Common

Net Loss Attributable to Common Stockholders Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Attributable to Common Stockholders Per Share	Net Loss Attributable to Common Stockholders Per Share Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards. Awards granted with performance conditions are excluded from the shares used to compute diluted earnings per share until the performance conditions associated with the awards are met. The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders, basic and diluted $ (25,747) $ (18,154) $ (47,173) $ (33,589) Denominator Weighted-average shares used to compute net income per share, basic and diluted 67,985,664 66,790,755 67,842,372 66,029,307 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (0.38) $ (0.27) $ (0.70) $ (0.51) Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: Three and six months ended June 30, 2022 2021 Options to purchase common stock 7,750,612 7,619,929 Restricted stock units 4,241,025 470,985 Total 11,991,637 8,090,914

Segments

Segments	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segments	Segments Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has one operating segment. The Company’s principal operations and decision-making functions are located in the United States. The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 North America $ 9,891 $ 8,874 $ 23,585 $ 16,236 Asia Pacific (1) 7,201 9,268 12,236 17,699 Europe 2,058 1,108 3,535 3,943 $ 19,150 $ 19,250 $ 39,356 $ 37,878 (1) Asia Pacific includes Australia. As of June 30, 2022 and December 31, 2021, substantially all of the Company’s long-lived assets were located in the United States .

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn July 21, 2022, to improve efficiency and manage operating expenses the Company terminated the employment of approximately 12% of total full-time employees. The Company estimates it will incur severance and employee-related restructuring costs of approximately $1.1 million related to this activity, substantially all of which the Company expects to incur in the third quarter of 2022.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America.
Short-Term Marketable Securities	Short-Term Marketable Securities The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities within “current assets” on the Company’s condensed consolidated balance sheets. The Company records these securities at fair value and accounts for the net unrealized gains and losses related to them as part of “other comprehensive loss” on its condensed consolidated statement of comprehensive loss. The Company records realized gains and losses on the sale of its marketable securities in “Other income, net” in its condensed consolidated statement of operations. At each reporting date, the Company performs an evaluation of impairment of its short-term available-for-sale marketable debt securities to determine if the fair value of its investment is less than its amortized cost basis. Impairment is assessed at the individual security level. Factors considered in determining whether an investment is impaired include the Company’s intent and ability to hold the investment until the recovery of its amortized cost basis, any historical failure of the issuer to make scheduled interest or principal payments, any change to the rating of the security by a rating agency, any adverse legal or regulatory events affecting the issuer or issuer’s industry, and any significant deterioration in economic conditions.
Stock-Based Compensation	Stock-Based Compensation The Company maintains an incentive compensation plan under which stock options and restricted stock units (“RSU”) are granted to employees and non-employee consultants. Stock-based compensation expense is based on the grant date fair value of the award. The Company determines the fair value of RSUs based on the closing value of its stock price listed on the Nasdaq at the date of the grant. The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value. The fair value of stock options and RSUs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis. For performance stock options and awards not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed. The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities	The following table summarizes the amortized costs and carrying value of the Company’s available-for-sale marketable debt securities, by major security type, as of June 30, 2022 (in thousands): As of June 30, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 5,395 $ — $ (8) $ 5,387 U.S. government securities 3,982 — (8) 3,974 Total $ 9,377 $ — $ (16) $ 9,361

Revenue From Contracts With C_2

Revenue From Contracts With Customers (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following table depicts the disaggregation of revenue by type of customer or sales channel and market segment as defined by nature of workflows and activities of the end customer (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Type of Sales Channel Direct sales channel $ 14,067 $ 10,103 $ 29,553 $ 20,542 Distributor channel 5,083 9,147 9,803 17,336 Net revenues $ 19,150 $ 19,250 $ 39,356 $ 37,878 Market Antibody therapeutics $ 12,984 $ 13,672 $ 27,209 $ 28,786 Synthetic biology 2,067 1,856 4,539 3,840 Agricultural biology 1,854 — 3,345 — Gene therapy 2,028 2,058 3,802 3,283 Cell therapy 217 1,664 461 1,969 Net revenues $ 19,150 $ 19,250 $ 39,356 $ 37,878
Schedule of receivables, contract assets and deferred revenue from contracts with customers	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): June 30, December 31, Trade accounts receivable $ 13,815 $ 25,942 Contract assets, which are included in “Prepaid expenses and other current assets” $ 3,765 $ 1,736 Contract assets, long-term, which are included in “Other assets” $ 996 $ 1,070 Deferred revenue (current) $ 8,694 $ 12,128 Deferred revenue (non-current) $ 1,221 $ 2,187
Schedule of sales-type lease maturity	The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of June 30, 2022 (in thousands): Year ending December 31, Sales-Type Remainder of 2022 $ 1,212 2023 445 2024 853 Total undiscounted cash flows 2,510 Less: unearned income 305 Total amounts due from customers $ 2,205

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	The following table shows the components of inventory (in thousands): June 30, December 31, Raw materials $ 10,861 $ 8,296 Finished goods 4,803 6,251 Total $ 15,664 $ 14,547
Schedule of prepaid expenses and other current assets	The following table shows the components of prepaid expenses and other current assets (in thousands): June 30, December 31, Contract asset $ 3,765 $ 1,736 Vendor deposits 2,679 2,802 Deferred costs 537 561 Prepaid insurance 399 2,944 Other (1) 3,226 3,942 Total $ 10,606 $ 11,985 (1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.
Schedule of accrued expenses and other current liabilities	The following table shows the components of accrued expenses and other current liabilities (in thousands): June 30, December 31, Accrued payroll and employee related expenses $ 6,400 $ 6,757 Lease liability – short-term 3,046 2,941 Accrued product warranty 752 1,085 Accrued legal expenses 1,087 504 Other (1) 660 1,138 Total $ 11,945 $ 12,425 (1) Other includes primarily accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): June 30, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 32,233 $ 32,233 $ — $ — Commercial paper 22,595 — 22,595 — U.S. government securities 5,986 — 5,986 — Total cash equivalents 60,814 32,233 28,581 — Debt securities, available for sale: Commercial paper 5,387 — 5,387 — U.S. government securities 3,974 — 3,974 — Total debt securities, available for sale 9,361 — 9,361 — Total assets measured at fair value $ 70,175 $ 32,233 $ 37,942 $ — December 31, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 25,138 $ 25,138 $ — $ — Total cash equivalents $ 25,138 $ 25,138 $ — $ —
Schedule of financial instruments not measured at fair value	The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): June 30, 2022 December 31, 2021 Carrying Fair Value Carrying Fair Value Long-term debt, including current maturities $ 19,794 $ 19,287 $ 19,762 $ 19,298

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment, net comprised the following (in thousands): June 30, December 31, Equipment, tooling and molds $ 38,599 $ 33,972 Computer software and equipment 2,929 3,019 Furniture, fixtures and other 1,957 1,891 Leasehold improvements 10,820 6,105 Construction in process 778 4,803 Total property and equipment 55,083 49,790 Less: Accumulated depreciation (25,766) (21,798) Property and equipment, net $ 29,317 $ 27,992

Leases (Table)

Leases (Table)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of operating lease liabilities maturity	Future payments associated with the Company’s operating lease liabilities as of June 30, 2022 is as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, Remainder of 2022 $ 2,101 2023 4,273 2024 4,355 2025 4,486 2026 4,621 Thereafter 12,223 Total undiscounted lease payments 32,059 Less: implied interest (4,811) Less: tenant improvement allowances receivable (65) Present value of operating lease payments 27,183 Less: current portion (1) (3,046) Total long-term operating lease liabilities $ 24,137 (1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”
Schedule of supplemental cash flow information related to operating leases	The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Six months ended June 30, 2022 Six months ended June 30, 2021 Right-of-use assets obtained for new operating lease liabilities $ — $ — Cash paid for amounts included in the measurement of lease liabilities $ 1,070 $ 796
Schedule of additional information related to operating leases	The following summarizes additional information related to operating leases: June 30, 2022 December 31, 2021 Weighted-average remaining lease term (years) 7.02 7.51 Weighted-average discount rate 4.67 % 4.67 %

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of payments due on notes payable	The following is a schedule of payments due on notes payable as of June 30, 2022 (in thousands): June 30, Year Ending December 31: Remainder of 2022 $ 426 2023 6,617 2024 10,406 2025 4,210 Total payments due 21,659 Less: Interest payments, loan discounts and financing costs (1,865) Current portion, less loan discounts and financing costs — Notes payable, net of current portion $ 19,794

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation	Stock-based compensation related to the Company's stock-based awards was recorded as an expense and allocated as follows (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Cost of sales $ 68 $ 63 $ 119 $ 105 Research and development 2,292 1,599 3,873 2,660 General and administrative 2,318 2,497 4,529 3,869 Sales and marketing 1,887 1,470 3,437 3,489 Total stock-based compensation $ 6,565 $ 5,629 $ 11,958 $ 10,123

Statements of Cash Flows (Table

Statements of Cash Flows (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of cash flow, supplemental disclosures	The supplemental cash flow information consists of the following (in thousands): Six months ended June 30, 2022 2021 Cash paid for interest $ 278 $ 681 Cash paid for income taxes $ — $ 3 Non-cash investing and financing activities Inventory transferred to property and equipment (1) $ — $ 3,827 Change in accounts payable and accrued liabilities related to purchases of property and equipment $ (699) $ 723 (1) The non-cash transfer of inventory to property and equipment principally relates to Beacons that were transferred to the Company’s BioFoundry operations in the first and second quarter of 2021. As a result of the growth of the Company’s BioFoundry operations, including growth in the number of Beacons used to fulfill strategic partnerships and services agreements, beginning in the third quarter of 2021, Beacons that at inception are planned to be used in the Company’s BioFoundry operations will be categorized as “Purchase of property and equipment.”

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of product warranty liability	The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Balance, beginning of period $ 914 $ 1,268 $ 1,085 $ 1,271 Adjustments to existing warranties (185) (148) (430) (366) Provision for new warranties 179 242 342 617 Settlement of pre-existing warranties (156) (172) (245) (332) Balance, end of period $ 752 $ 1,190 $ 752 $ 1,190

Net Loss Attributable to Comm_2

Net Loss Attributable to Common Stockholders Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per common share	The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders, basic and diluted $ (25,747) $ (18,154) $ (47,173) $ (33,589) Denominator Weighted-average shares used to compute net income per share, basic and diluted 67,985,664 66,790,755 67,842,372 66,029,307 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (0.38) $ (0.27) $ (0.70) $ (0.51)
Schedule of antidilutive securities excluded from computation of earnings per share	The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: Three and six months ended June 30, 2022 2021 Options to purchase common stock 7,750,612 7,619,929 Restricted stock units 4,241,025 470,985 Total 11,991,637 8,090,914

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Summary of revenue by geographic areas	The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 North America $ 9,891 $ 8,874 $ 23,585 $ 16,236 Asia Pacific (1) 7,201 9,268 12,236 17,699 Europe 2,058 1,108 3,535 3,943 $ 19,150 $ 19,250 $ 39,356 $ 37,878 (1) Asia Pacific includes Australia.

The Company and Basis of Pres_3

The Company and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (25,747)	$ (18,154)	$ (47,173)	$ (33,589)
Accumulated deficit	(310,781)		(310,781)		$ (263,608)
Cash, cash equivalents, and marketable securities	$ 152,400		$ 152,400

Marketable Securities - Unreali

Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 9,377
Unrealized Gains	0
Unrealized Losses	(16)
Fair Value	9,361
Commercial paper
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	5,395
Unrealized Gains	0
Unrealized Losses	(8)
Fair Value	5,387
U.S. government securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	3,982
Unrealized Gains	0
Unrealized Losses	(8)
Fair Value	$ 3,974

Significant Risks and Uncerta_2

Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) - Customer	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	20%	27%	16%	14%
Revenue | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	11%	18%	11%	11%
Revenue | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage	10%	11%	10%	10%
Accounts Receivable | Customer One
Concentration Risk [Line Items]
Concentration risk percentage			27%		15%
Accounts Receivable | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage			12%		11%
Accounts Receivable | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage			11%		11%

Revenue From Contracts With C_3

Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net revenues	$ 19,150	$ 19,250	$ 39,356	$ 37,878
Antibody therapeutics
Disaggregation of Revenue [Line Items]
Net revenues	12,984	13,672	27,209	28,786
Synthetic biology
Disaggregation of Revenue [Line Items]
Net revenues	2,067	1,856	4,539	3,840
Agricultural biology
Disaggregation of Revenue [Line Items]
Net revenues	1,854	0	3,345	0
Gene therapy
Disaggregation of Revenue [Line Items]
Net revenues	2,028	2,058	3,802	3,283
Cell therapy
Disaggregation of Revenue [Line Items]
Net revenues	217	1,664	461	1,969
Direct sales channel
Disaggregation of Revenue [Line Items]
Net revenues	14,067	10,103	29,553	20,542
Distributor channel
Disaggregation of Revenue [Line Items]
Net revenues	$ 5,083	$ 9,147	$ 9,803	$ 17,336

Revenue from Contracts with C_4

Revenue from Contracts with Customer (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 6.4		$ 6.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	9.9		9.9		$ 14.3
Contract liability , revenue recognized	2.7		9.9
Lease income	$ 0	$ 1	$ 0	$ 2.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	20%		20%
Remaining performance obligation, period	12 months		12 months

Revenue From Contracts With C_5

Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Trade accounts receivable	$ 13,815	$ 25,942
Contract assets, which are included in “Prepaid expenses and other current assets”	3,765	1,736
Contract assets, long-term, which are included in “Other assets”	996	1,070
Deferred revenue (current)	8,694	12,128
Deferred revenue (non-current)	$ 1,221	$ 2,187

Revenue From Contracts With C_6

Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Revenue from Contract with Customer [Abstract]
Remainder of 2022	$ 1,212
2023	445
2024	853
Total undiscounted cash flows	2,510
Less: unearned income	305
Total amounts due from customers	$ 2,205

Balance Sheet Accounts (Invento

Balance Sheet Accounts (Inventory) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 10,861	$ 8,296
Finished goods	4,803	6,251
Total	$ 15,664	$ 14,547

Balance Sheet Accounts (Prepaid

Balance Sheet Accounts (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract asset	$ 3,765	$ 1,736
Vendor deposits	2,679	2,802
Deferred costs	537	561
Prepaid insurance	399	2,944
Other	3,226	3,942
Total	$ 10,606	$ 11,985

Balance Sheet Accounts (Accrued

Balance Sheet Accounts (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and employee related expenses	$ 6,400	$ 6,757
Lease liability - short-term [Extensible Enumeration]	Total	Total
Lease liability – short-term	$ 3,046	$ 2,941
Accrued product warranty	752	1,085
Accrued legal expenses	1,087	504
Other	660	1,138
Total	$ 11,945	$ 12,425

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Assets and Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	$ 9,361	$ 0
Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	60,814	25,138
Total debt securities, available for sale	9,361
Total assets measured at fair value	70,175
Fair Value, Measurements, Recurring | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	5,387
Fair Value, Measurements, Recurring | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	3,974
Fair Value, Measurements, Recurring | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	32,233	25,138
Fair Value, Measurements, Recurring | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	22,595
Fair Value, Measurements, Recurring | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	5,986
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	32,233	25,138
Total debt securities, available for sale	0
Total assets measured at fair value	32,233
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	32,233	25,138
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	28,581	0
Total debt securities, available for sale	9,361
Total assets measured at fair value	37,942
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	5,387
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	3,974
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	22,595
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	5,986
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0	0
Total debt securities, available for sale	0
Total assets measured at fair value	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0	$ 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | U.S. government securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Schedule of Financial Instruments Not Measured at Fair Value) (Details) - Significant Other Observable Inputs (Level 2) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 19,794	$ 19,762
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 19,287	$ 19,298

Property and Equipment, net (Sc

Property and Equipment, net (Schedule of Property and Equipment) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 55,083	$ 49,790
Less: Accumulated depreciation	(25,766)	(21,798)
Property and equipment, net	29,317	27,992
Equipment, tooling and molds
Property, Plant and Equipment [Line Items]
Total property and equipment	38,599	33,972
Computer software and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,929	3,019
Furniture, fixtures and other
Property, Plant and Equipment [Line Items]
Total property and equipment	1,957	1,891
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	10,820	6,105
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 778	$ 4,803

Property and Equipment, net (Na

Property and Equipment, net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 2,500	$ 1,400	$ 4,431	$ 2,654

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) facility	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) facility	Jun. 30, 2021 USD ($)	Sep. 30, 2021
Lessee, Lease, Description [Line Items]
Number of facilities | facility	2		2
Rent expense	$ 1.4	$ 0.9	$ 2.5	$ 1.7
Variable lease payments	$ 1	$ 0.6	$ 1.8	$ 1.1
Office and Laboratory Operations
Lessee, Lease, Description [Line Items]
Term of lease					7 years

Leases (Maturity Schedule of Op

Leases (Maturity Schedule of Operating Lease Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of 2022	$ 2,101
2023	4,273
2024	4,355
2025	4,486
2026	4,621
Thereafter	12,223
Total undiscounted lease payments	32,059
Less: implied interest	(4,811)
Less: tenant improvement allowances receivable	(65)
Present value of operating lease payments	27,183
Less: current portion	(3,046)	$ (2,941)
Total long-term operating lease liabilities	$ 24,137	$ 24,337

Leases (Schedule of Supplementa

Leases (Schedule of Supplemental Cash Flow Information Related to Operating Leases) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Right-of-use assets obtained for new operating lease liabilities	$ 0	$ 0
Cash paid for amounts included in the measurement of lease liabilities	$ 1,070	$ 796

Leases (Schedule of Additional

Leases (Schedule of Additional Information Related to Operating Leases) (Details)	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	7 years 7 days	7 years 6 months 3 days
Weighted-average discount rate	4.67%	4.67%

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	May 23, 2018
Debt Instrument [Line Items]
Interest cost		$ 200,000	$ 400,000	$ 500,000	$ 700,000
Notes Payable | EWB Loan
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 20,000,000
Notes Payable | Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 20,000,000		$ 20,000,000		$ 20,000,000
Note payable, term (in years)	48 months
Interest rate	4.17%		4.17%		4.17%
Interest-only period	24 months
Interest-only period with extension	36 months
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 10,000,000		$ 10,000,000		$ 10,000,000
Amount outstanding		$ 0		$ 0
Line of Credit | Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.70%

Notes Payable (Schedule of Paym

Notes Payable (Schedule of Payment Due on Notes Payable) (Details) - Notes Payable - Term Loan $ in Thousands	Jun. 30, 2022 USD ($)
Debt Instrument [Line Items]
Remainder of 2022	$ 426
2023	6,617
2024	10,406
2025	4,210
Total payments due	21,659
Interest payments, loan discounts and financing costs	(1,865)
Current portion, less loan discounts and financing costs	0
Notes payable, net of current portion	$ 19,794

Stock Compensation Plans (Stock

Stock Compensation Plans (Stock-Based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 6,565	$ 5,629	$ 11,958	$ 10,123
Cost of sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	68	63	119	105
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	2,292	1,599	3,873	2,660
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	2,318	2,497	4,529	3,869
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 1,887	$ 1,470	$ 3,437	$ 3,489

Stock Compensation Plans (Narra

Stock Compensation Plans (Narrative) (Details) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended
	May 19, 2022 USD ($) $ / shares shares	Mar. 10, 2022 shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share) | $ / shares	$ 4.91
Stock option expense | $			$ 6,565	$ 5,629	$ 11,958	$ 10,123
Chief Executive Officer | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price goal multiplier of share price on date of grant		2
Chief Executive Officer | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price goal multiplier of share price on date of grant		20
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options repriced (in shares)	763,307
Stock option expense | $	$ 1,500		500
RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option expense | $	$ 1,500		$ 55
RSUs granted (in shares)	353,625
RSU | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs granted (in shares)		1,017,177
Stock options | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)		339,059
Vesting period		3 years
Expiration period		10 years
PSO | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)		678,118
Vesting period		7 years
Expiration period		10 years
Shares vested (in shares)					0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 4	$ 26	$ 24	$ 43

Statements of Cash Flows (Detai

Statements of Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash paid for interest	$ 278	$ 681
Cash paid for income taxes	0	3
Non-cash investing and financing activities
Inventory transferred to property and equipment	0	3,827
Change in accounts payable and accrued liabilities related to purchases of property and equipment	$ (699)	$ 723

Commitment and Contingencies (N

Commitment and Contingencies (Narrative) (Details)		1 Months Ended			6 Months Ended
	Jul. 01, 2021 claim patent	Dec. 31, 2021 investedCompany	Oct. 31, 2020 claim	Aug. 31, 2020 claim	Jun. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Number of counts in amended complaint			3
Loss contingency accrual | $					$ 0
Number of company invested | investedCompany		3
Assurance-type warranty period					13 months
AbCellera and UBC
Loss Contingencies [Line Items]
Case management order, maximum number of patents allegedly infringed | patent	2
Case management order, maximum asserted patent claims per patent	4
AbCellera, Unfair Competition
Loss Contingencies [Line Items]
Counter claims filed				2
AbCellera, Non-Infringement
Loss Contingencies [Line Items]
Counter claims filed				1

Commitment and Contingencies (P

Commitment and Contingencies (Product Warranty) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance, beginning of period	$ 914	$ 1,268	$ 1,085	$ 1,271
Adjustments to existing warranties	(185)	(148)	(430)	(366)
Provision for new warranties	179	242	342	617
Settlement of pre-existing warranties	(156)	(172)	(245)	(332)
Balance, end of period	$ 752	$ 1,190	$ 752	$ 1,190

Net Loss Attributable to Comm_3

Net Loss Attributable to Common Stockholders Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator
Net loss attributable to common stockholders, basic	$ (25,747)	$ (18,154)	$ (47,173)	$ (33,589)
Net loss attributable to common stockholders, diluted	$ (25,747)	$ (18,154)	$ (47,173)	$ (33,589)
Denominator
Weighted-average shares used to compute net income per share, basic (in shares)	67,985,664	66,790,755	67,842,372	66,029,307
Weighted-average shares used to compute net income per share, diluted (in shares)	67,985,664	66,790,755	67,842,372	66,029,307
Net loss per share
Net loss attributable to common stockholders per share, basic (in dollars per share)	$ (0.38)	$ (0.27)	$ (0.70)	$ (0.51)
Net loss attributable to common stockholders per share, diluted (in dollars per share)	$ (0.38)	$ (0.27)	$ (0.70)	$ (0.51)

Net Loss Attributable to Comm_4

Net Loss Attributable to Common Stockholders Per Share (Schedule of Antidilutive Securities) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	11,991,637	8,090,914	11,991,637	8,090,914
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	7,750,612	7,619,929	7,750,612	7,619,929
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	4,241,025	470,985	4,241,025	470,985

Segments (Details)

Segments (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | segment			1
Total revenue	$ 19,150	$ 19,250	$ 39,356	$ 37,878
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	9,891	8,874	23,585	16,236
Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	7,201	9,268	12,236	17,699
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 2,058	$ 1,108	$ 3,535	$ 3,943

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	Jul. 21, 2022	Sep. 30, 2022
Forecast
Subsequent Event [Line Items]
Severance and employee-related restructuring costs		$ 1.1
Subsequent Event
Subsequent Event [Line Items]
Total full-time employees (in percent)	12%